New Articles

Easy Peel Film Packaging Demand Expands Across Food and Beverage Sector

easy peel

Easy Peel Film Packaging Demand Expands Across Food and Beverage Sector

The easy peel film packaging market is witnessing significant growth due to persistent demand for easy-to-use, cost-effective durable, eco-friendly, and moisture & water-resistant packaging solutions in various end-use industries such as pharmaceutical, food & beverage, and others. In the food & beverage industry, easy peel film finds applications in the packaging of many processed or ready-made food products such as tofu, jellies, butter, yogurt, muffins, cakes, and others.

Growing consumer inclination towards packaged food products in developed, as well as developing countries, is expected to augment the demand for food-grade easy peel films. Seafood is a commonly consumed product across various nations, where the packaging can help deliver quality products to consumers.

As per the U.S. Department of Agriculture (USDA), consumers, businesses, and government entities in the United States had combined spent almost US$1.77 trillion on food & beverages in grocery and retailer shops in 2019. This expenditure on packaged food products is likely to increase further, owing to the rising health concerns amid the COVID-19 outbreak.

Easy peel film packaging solutions provide a robust barrier to dust, moisture, and other harmful impurities present in the environment and help in increasing product shelf life. Polyethylene (PE), polyethylene terephthalate (PET), cast polypropylene (CPP), and polyester & laminated material are the prominent easy peel film packaging materials. Polyethylene (PE) film offers high strength, gas permeability, easy acquisition, and low-cost benefits due to which the material is chiefly used in packaging solutions for fruits and vegetables.

The growing trade of fruits and vegetables mainly in developed regions should increase PE film demand to a large extent. According to Global Market Insights, Inc., the global easy peel film packaging market size is predicted to expand at a notable rate through 2027.

As per the Ministry of Foreign Affairs (CBI), the European imports of processed fruits and vegetables were recorded at 24 million tons in 2019.

The easy peel film packaging products with respect to transparency are categorized as transparent and opaque. Opaque films are becoming key packaging material for e-commerce businesses. Opaque films eliminate the utilization of bulky packages and other packaging materials such as fillers and tapes, which further helps in reducing shipping costs.

Growing R&D expenditure by prominent industry players could create lucrative growth opportunities for the easy peel film market and new product development. For instance, Berry Global Group, Inc. has recently announced an investment of over US$70 million to support ongoing developments in consumer packaging films primarily for food & beverage and e-commerce applications.

North America’s easy peel film packaging industry is predicted to witness substantial growth, owing to the high demand for packaged and processed food products among consumers. Significant rise in per capita income and increasing health awareness due to escalating viral infections such as coronavirus have urged Americans to adopt packaged food products for better hygiene, rather and outdoor dining. Moreover, increasing preference towards nutritional supplements and bakery & confectionery products is expected to complement the regional industry landscape.

life sciences therapy

Life Sciences Real Estate in the Time of COVID-19

Increased funding plus employees that need an office makes the Life Sciences real estate sector resilient in a global pandemic.

The life sciences industry has become one of the most talked-about sectors as the entire world races to find a vaccine for COVID-19. In the first six months of 2020, investors have spent more than $16 billion on life sciences, while the National Institutes of Health (NIH) continues to increase its grants. In 1994, NIH gave out $11 billion in grants, and by the end of 2019, that number jumped to $39.1 billion – fueled by COVID-19-related therapeutics, antibody tests, and vaccines. Additionally, the aging U.S. population needing life-sustaining care, wellness-conscious millennials, and a prescription drug market on track to reach $1 trillion by 2022 has also played a part.

In an effort to continue research, development, and production, life sciences companies, owners, and operators of laboratories and office space are fast-tracking the use of current and new technologies.

The Importance of Technology

Over the years, technology has improved the R&D landscape of life sciences by significantly reducing costs. Connections between tech and biotech are creating more targeted drug development, replacing the previous time-consuming theories. Nowadays, interaction simulations can be run at the click of a button, and clinical trials can be done quicker and cheaper through technology efficiencies. Artificial Intelligence (AI) has become so valuable in finding links in the ever-growing global data resources. Also, it has created more platforms and business opportunities for biotech companies to utilize.

These days, many work-from-home policies are hard to apply to the work done in labs. So, life sciences companies have relied on scheduling and remote communication tech to coordinate calendars for on-site employees to conduct activities that cannot be done at home. Calendar tools with features that allow all employees access to real-time scheduling software have also become more widespread. And some companies have even sped up the integration of cloud-based platforms into ongoing research. This movement toward remote research tools has been inspired by the pandemic, allowing researchers to analyze data from home and focus during their time in the lab.

Market Applications

The pandemic has forced pharmaceutical companies to confront new challenges to traditional methods when conducting clinical trials. Many life sciences companies have had to ramp up fast, integrate virtual engagement into their clinical trial protocols, all while using telehealth technologies to connect with trial participants more widely than ever before.

In fact, in March 2020, the U.S. Food and Drug Administration issued guidance bolstering clinical trial sponsors to “evaluate whether alternative methods for safety assessments (phone contact, virtual visit, alternative location for the assessment…) could be implemented if necessary.  Some industry experts this transition to more tech-focused engagement would have taken many more years without the momentum ignited by the pandemic.

Additionally, COVID-19 has had a monumental impact on how technology is used in today’s drug development and drug applications. Many life sciences companies are increasing the use of AI in the search for a vaccine and identifying existing drugs that may be repurposed for therapeutic solutions. AI can make data collection and analysis so much more efficient in clinical trials and can be used to synthesize data too fast to determine drug candidates’ safety and efficacy.

Who’s Investing?

Today, with a significant focus on health and wellness, life science companies expand with large investments from financial and corporate venture capital groups. As a result, investment capital is surging into the life science market. The U.S. is the leader for investment by a lot, with China right behind it, having had some large investment rounds. While the life science market is healthy, other industries are in distress. As we all know, retail is in trouble, and corporate offices are struggling, especially in the wake of COVID-19. With the increased telecommuting, the future of the office sector is uncertain. So, life sciences have become a focus in the real estate industry, making it attractive to investors looking for an opportunity.

There is a lot of VC money being invested in life sciences, so these companies are well-capitalized. This sector has traditionally weathered economic challenges well. Think tech crash of the early 2000s and the Great Recession as examples. Since life science companies like to invest in their premises and stay long term, rents are higher, making life sciences a really attractive investment opportunity right now. Rents are continuing to increase, with sustained growth in most areas, and that growth has been consistent over time, making for a smart investment.

Key Issues to Watch For

To manage the impact of the COVID-19 pandemic, owners and managers of properties that house life sciences offices, manufacturing, and laboratory space have been able to apply many of the pandemic-related solutions that they have used elsewhere. Given that many labs are typically single-tenant buildings, landlords can cater to unique concerns. However, life sciences tenants can be less experienced than others, presenting landlords and property managers with an opportunity to add value by providing tenants with advice on the solutions they have seen work effectively across the buildings they own and manage, such as sanitization and touchless technologies.

Long term, some see the pandemic and corresponding focus on the design and repositioning of spaces for tenants as a continuing driver toward developing healthy buildings. The users of life science office and lab space are more than likely to be some of the most highly-educated consumers of real estate in any market. For them, the management of space in a sustainable way has become an expectation instead of a plus. Moving forward, competitive advantage will be the integration of health and wellness facilities and technologies as we enter the post-COVID-19 “new normal.”

Where Do We Go From Here?

Looking into the future, as the life sciences boom continues in the real estate industry, owners and operators must be aware of how they and their tenants can harness the right technology to address the obstacles from the pandemic. To successfully market spaces to biotech, pharmaceutical, and medical device companies, real estate developers must be mindful of this challenge, as their users are likely to be more tech-savvy than the average real estate consumer. On the other hand, owners of older spaces hoping to reposition them as an office or lab space must convince potential tenants to integrate innovative technologies as effectively as developers of new modern spaces.

As real estate owners, investors, and operators move into the post-COVID-19 world with a focus on life sciences, they will need to demonstrate to the market that they have a keen understanding of current issues and solutions applicable to life sciences tenants and how the right technology can solve them.


Louis Lehot is the founder of L2 Counsel. Louis is a corporate, securities, and M & A lawyer, and he helps his clients, whether they be public or private companies, financial sponsors, venture capitalists, investors or investment banks, in forming, financing, governing, buying and selling companies. He is formerly the co-managing partner of DLA Piper’s Silicon Valley office and co-chair of its leading venture capital and emerging growth company team. 

L2 Counsel, P.C. is an elite boutique law firm based in Silicon Valley designed to serve entrepreneurs, innovative companies and investors with sound legal strategies and solutions. 

Adobe to Close Its China Research & Development Center

Mountain View, CA – Adobe Systems has said it will shutter its research and development center in China because of what the US software giant says are the country’s “increasingly unfavorable” business conditions.


The Beijing facility opened its doors on October 2008 with more than 300 people involved in developing software products specifically designed for the Chinese market.

The process of closing down the center will reportedly continue through the end of the year.


Lay-offs have already started with about 300 people likely to face job cuts. Some 30 employees, the company said, will be relocated to the company’s headquarters in Northern California or to branch offices in India.


“We are committed to China as a long-term market, and will continue our sales presence nationally as always,” the company said in a statement released to the press.


The move, it said, “will not affect Adobe’s overall level of investment in R&D and is not an indication of financial performance in China or worldwide.”


Adobe did say it would, however, maintain its Chinese sales offices in Shanghai, Beijing, Guangzhou, Shenzhen, Hong Kong.


The Silicon Valley-based company is just one of several US-based high-tech firms that have come under increasing scrutiny by the Chinese government over allegedly illegal business practices.


Microsoft and Qualcomm are currently being probed, while Adobe recently had its office in Beijing raided by Chinese officials as part of an “anti-monopoly investigation” aimed at its ‘Office’ suite of programs and ‘Windows’ operating system, which is used on the vast majority of computers in China.


The head of the government agency investigating Microsoft for what it calls “monopoly actions” said last month that the probe includes the way the US giant distributes its media player and browser.


Speculation by industry analysts draws a connecting line between the investigations by Beijing and the US government’s indictment earlier this year of five members of a Chinese military unit for allegedly hacking into the computer systems of several major US companies to steal trade secrets – a charge the Chinese government vehemently denies.



GlobalLogic Opens New Facility in Slovakia

San Jose, CA – GlobalLogic recently opened the doors at its new engineering center in Kosice, Slovakia.

The new R&D innovation center in what is commonly referred to as the “Silicon Valley” of Europe “will provide more opportunities for the growth of the company, its customers and global product development,” the company said.

As a member of the EU, and its close proximity to the US and Europe, Slovakia, it added, “is considered one of the most rapidly growing economies in Europe and has a strong focus on R&D and innovation in the technology sector.”

Headquartered in San Jose, California, and McLean, Virginia, GlobalLogic was founded in 2000 and operates design and engineering centers in the UK, India, China, Ukraine, Argentina, Israel and Chile.

The company works with both start-ups and industry leaders, including many of the world’s top hardware, software, and consumer brands.



TRW Automotive Opens New China Tech Center

Livonia, MI – TRW Automotive Holdings Corp. has opened its largest ever Technical Center – a 200,000 square foot facility – in Anting, China.

The facility houses more than 20 scientific testing labs supporting all of TRW’s main business areas including braking, steering and suspension, occupant safety and safety electronics, will employ more than 1,200 members of engineering, research and technical staff.

The new Anting Technical Center will also house research & development, engineering design & application, and testing & validation activities across all of TRW’s product lines, as well as providing customers with direct access to technical and commercial services, the company said.

With 2013 sales of $17.4 billion, TRW Automotive operates in 24 countries and employs approximately 65,000 people worldwide.

The company’s products include integrated vehicle control and driver assist systems, braking systems, steering systems, suspension systems, occupant safety systems (seat belts and airbags), electronics, engine components, fastening systems and aftermarket replacement parts and services.